2024-515686-34-00招募中2 期
A phase II study of Pembrolizumab plus Carboplatin in BRCA-related metastatic breast cancer
Azienda Ospedaliero Universitaria Di Modena, Azienda Ospedaliero Universitaria Di Modena, Azienda Ospedaliero Universitaria Di Modena4 个研究点 分布在 1 个国家目标入组 53 人开始时间: 2024年11月12日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 53
- 试验地点
- 4
- 主要终点
- The objective response rate
研究概览
简要总结
The ORR (complete response plus partial response) will be evaluated according to RECIST v1.1 criteria
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- •Be willing and able to provide written informed consent/assent for the trial.
- •Be >=18 years of age on day of signing informed consent.
- •Patients must have metastatic confirmed breast cancer
- •Disease progression by radiological techniques within 12 months prior to signing informed consent
- •Documented mutation in BRCA1 or BRCA2 genes that is predicted to be deleterious or suspected deleterious (unknown significance variants)
- •Presence of at least 1 measurable lesion based on RECIST v1.
- •Prior chemotherapy with anthracyclines and taxanes has to be administered.
- •No more than one line of chemotherapy for advanced disease has to be administered
- •In case of luminal tumors hormonal treatments for advanced disease can be administered before
- •Be willing to provide tissue from a newly obtained core or excisional biopsy of a tumor lesion. Newly-obtained is defined as a specimen obtained up to 6 weeks (42 days) prior to initiation of treatment on Day
- •Subjects for whom newly-obtained samples cannot be provided (e.g. inaccessible or subject safety concern) may submit an archived specimen
- •Have a performance status of 0 or 1 on the ECOG Performance Scale.
- •Life expectancy of greater than 3 months
- •Demonstrate adequate organ function as defined. All screening labs should be performed within 10 days of treatment initiation.
排除标准
- •Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.
- •Has a benign variant of BRCA1/2 genes
- •Has received more than one line of chemotherapy for advanced disease
- •Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug.
- •Has a known history of active TB (Bacillus Tuberculosis)
- •Has severe hypersensitivity (=Grade 3) to pembrolizumab and/or any of its excipients.
- •Has had an allogenic tissue/solid organ transplant
- •Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study Day 1 or who has not recovered (i.e., = Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier.
- •Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or who has not recovered (i.e., = Grade 1 or at baseline) from adverse events due to a previously administered agent. - Note: Subjects with = Grade 2 neuropathy are an exception to this criterion and may qualify for the study. - Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.
- •Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer.
- •Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment. This exception does not include carcinomatous meningitis which is excluded regardless of clinical stability.
- •Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment and is allowed.
- •Has a history of (non-infectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.
- •Has an active infection requiring systemic therapy.
- •Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject’s participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
- •Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
- •Has a positive urine pregnancy test within 72 hours prior to allocation. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. Is exclude also women pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the prescreening or screening visit through 120 days after the last dose of trial treatment.
结局指标
主要结局
The objective response rate
The objective response rate
次要结局
未报告次要终点
研究者
Laura Cortesi
Scientific
Azienda Ospedaliero Universitaria Di Modena
研究点 (4)
Loading locations...
相似试验
招募中
2 期
Pembrolizumab in combination with lenvatinib in patients with recurrent, persistent, metastatic or locally advanced vulvar cancer not amenable to curative surgery or radiotherapy (PIERCE)2024-515646-16-00AGO Research GmbH42
招募中
3 期
Phase 3 study of pembrolizumab vs chemotherapy in dMMR advanced or recurrent endometrial carcinoma2023-506361-56-00Merck Sharp & Dohme LLC153
进行中（未招募）
3 期
Phase 3 Study of Pembrolizumab with Maintenance Olaparib or Maintenance Pemetrexed in 1L Metastatic Nonsquamous NSCLC2023-509774-40-00Merck Sharp & Dohme LLC185
已完成
2 期
Phase 2 study of pembrolizumab and chemotherapy in participants with classical Hodgkin Lymphoma that has just been diagnosed2022-501615-14-00Merck Sharp & Dohme LLC50
招募中
2 期
Pembrolizumab + Lenvatinib for First Line Non-Clear Cell, Renal Cell Carcinoma2023-504944-32-00Merck Sharp & Dohme LLC59